These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9598178)

  • 1. The activity of dihydropyrimidine dehydrogenase in human blood cells.
    Van Kuilenburg AB; Van Lenthe H; Blom MJ; Mul EP; Van Gennip AH
    Adv Exp Med Biol; 1998; 431():823-6. PubMed ID: 9598178
    [No Abstract]   [Full Text] [Related]  

  • 2. No circadian variation of dihydropyrimidine dehydrogenase, uridine phosphorylase, beta-alanine, and 5-fluorouracil during continuous infusion of 5-fluorouracil.
    Van Kuilenburg AB; Poorter RL; Peters GJ; Van Gennip AH; Van Lenthe H; Stroomer AE; Smid K; Noordhuis P; Bakker PJ; Veenhof CH
    Adv Exp Med Biol; 1998; 431():811-6. PubMed ID: 9598176
    [No Abstract]   [Full Text] [Related]  

  • 3. Delayed hypersensitivity to 5-fluorouracil associated with reduced dihydropyrimidine dehydrogenase (DPD) activity.
    Duley JA; Nethersell AB
    Adv Exp Med Biol; 1998; 431():147-50. PubMed ID: 9598048
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
    van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH
    Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
    Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
    Int J Cancer; 2002 Sep; 101(3):253-8. PubMed ID: 12209976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe 5-fluorouracil toxicity caused by reduced dihydropyrimidine dehydrogenase activity due to heterozygosity for a G-->A point mutation.
    van Kuilenburg AB; Vreken P; Beex LV; De Abreu RA; van Gennip AH
    J Inherit Metab Dis; 1998 Jun; 21(3):280-4. PubMed ID: 9686375
    [No Abstract]   [Full Text] [Related]  

  • 7. Dihydropyrimidine dehydrogenase activity in a Korean population.
    Sohn DR; Cho MS; Chung PJ
    Ther Drug Monit; 1999 Apr; 21(2):152-4. PubMed ID: 10217332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients.
    Van Kuilenburg AB; van Lenthe H; Blom MJ; Mul EP; Van Gennip AH
    Br J Cancer; 1999 Feb; 79(3-4):620-6. PubMed ID: 10027339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A common progenitor for human myeloid and lymphoid cells.
    Prchal JT; Throckmorton DW; Carroll AJ; Fuson EW; Gams RA; Prchal JF
    Nature; 1978 Aug; 274(5671):590-1. PubMed ID: 672990
    [No Abstract]   [Full Text] [Related]  

  • 10. Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy.
    Zhang X; Diasio RB
    Pharmacogenomics; 2007 Mar; 8(3):257-65. PubMed ID: 17324113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydropyrimidine dehydrogenase activity in human blood mononuclear cells.
    Tuchman M; Roemeling RV; Hrushesky WA; Sothern RB; O'Dea RF
    Enzyme; 1989; 42(1):15-24. PubMed ID: 2528450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for dihydropyrimidine dehydrogenase deficiency.
    Grem JL
    Clin Cancer Res; 2005 Jul; 11(14):5067-8. PubMed ID: 16033817
    [No Abstract]   [Full Text] [Related]  

  • 13. Influence of liver dysfunction on dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.
    Nakada T; Yamauchi M; Toda G
    Gan To Kagaku Ryoho; 2002 Feb; 29 Suppl 1():230-5. PubMed ID: 11890111
    [No Abstract]   [Full Text] [Related]  

  • 14. Estimation of dihydropyrimidine dehydrogenase activity: does it have a role in cancer therapy?
    Collie-Duguid ES; McLeod HL; Cassidy J
    Ann Oncol; 2000 Mar; 11(3):255-7. PubMed ID: 10811489
    [No Abstract]   [Full Text] [Related]  

  • 15. The isozyme patterns of glucose-6-phosphate dehydrogenase in blood cells, bone marrow and other human tissues.
    Rozenszajn LA; Joseph D
    Biochim Biophys Acta; 1974 Sep; 364(1):38-44. PubMed ID: 4433564
    [No Abstract]   [Full Text] [Related]  

  • 16. On folic acid metabolism in human normal leukocytes of peripheral blood.
    Onicescu D; Stoica I; Popescu M
    Rev Roum Physiol; 1973; 10(2):163-8. PubMed ID: 4513657
    [No Abstract]   [Full Text] [Related]  

  • 17. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity.
    Van Kuilenburg AB; Vreken P; Beex LV; Meinsma R; Van Lenthe H; De Abreu RA; Van Gennip AH
    Adv Exp Med Biol; 1998; 431():293-8. PubMed ID: 9598078
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
    Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
    Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diaphorasic NADPH and NADH systems in human blood cells].
    Kaplan JC; Leroux A
    Bull Soc Chim Biol (Paris); 1970; 52(11):1243-9. PubMed ID: 4396253
    [No Abstract]   [Full Text] [Related]  

  • 20. Studies on the activities and properties of lysosomal hydrolases in fractionated populations of human peripheral blood cells.
    Nakagawa S; Kumin S; Nitowsky HM
    Clin Chim Acta; 1980 Feb; 101(1):33-44. PubMed ID: 6766826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.